- Open Access
OncodriveFML: a general framework to identify coding and non-coding regions with cancer driver mutations
© The Author(s). 2016
- Received: 11 February 2016
- Accepted: 31 May 2016
- Published: 16 June 2016
Distinguishing the driver mutations from somatic mutations in a tumor genome is one of the major challenges of cancer research. This challenge is more acute and far from solved for non-coding mutations. Here we present OncodriveFML, a method designed to analyze the pattern of somatic mutations across tumors in both coding and non-coding genomic regions to identify signals of positive selection, and therefore, their involvement in tumorigenesis. We describe the method and illustrate its usefulness to identify protein-coding genes, promoters, untranslated regions, intronic splice regions, and lncRNAs-containing driver mutations in several malignancies.
- Cancer drivers
- Non-coding regions
- Local functional mutations bias
- Non-coding drivers
Massive cancer genomic initiatives promoted by the advance of next generation sequencing technologies have uncovered the landscape of somatic mutations in cohorts of patients suffering from dozens of the most common tumor types [1, 2]. These initiatives, focused mostly on exome regions, demonstrated the pressing need to develop methods to identify protein-coding cancer drivers from the wealth of mutated genes in tumor genome . Several methods that identify genes whose mutational patterns significantly deviate from the expected behavior have been developed and validated [3–8]. These abnormal mutational patterns are caused by positive selection acting on the mutations in driver genes during the course of tumorigenesis and tumor evolution . A mutational frequency across a cohort of tumors that is significantly higher than the background mutation rate is the most intuitive and exploited signal of positive selection, implemented for example by computational approaches such as MuSiC  and MutSig . Nevertheless, the correct estimation of the background mutation rate of protein-coding genes requires accounting for many known—and probably also yet unknown—covariates, some of which can currently only be approximated . In 2012 we introduced a computational approach to detect a different signal of positive selection in driver genes: the bias towards the accumulation of high impacting mutations  across tumor samples. We proved that the top-ranking genes in their deviation of the average impact score of mutations observed from the expected average impact score of the same number of mutations in the given cohort—functional mutation (FM) bias—were bona fide cancer drivers.
Currently, the availability of hundreds of whole-genome sequences from tumors presents us with the unprecedented opportunity of identifying non-coding genomic regions involved in cancer development upon somatic mutations. Most of the approaches developed to scan protein-coding genes involved in tumorigenesis cannot be readily extended to the analysis of non-coding regions , and only few approaches designed to detect non-coding drivers have been recently proposed [11–14]. Moreover, catalogs of somatic mutations detected by targeted sequencing specific regions of genomes are accumulating as genome sequencing becomes routine in the clinical practice of oncology. The Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) , for example, has carried out the targeted deep sequencing of all exons and selected introns of 341 key cancer genes of thousands of tumors every year (https://www.sloankettering.edu/blog/expanding-impact-precision-medicine-fuel-discoveries). Most current methods to detect drivers rely on whole-exome or whole-genome sequencing data to build their background models for analysis. Therefore, they are unable to mine this rich data accumulating from targeted sequencing to further pinpoint the regions within cancer genes that exhibit signals of positive selection in different tumor types.
Here we propose a novel approach, OncodriveFML, to estimate the accumulated functional impact (FI) bias of tumor somatic mutations in genomic regions of interest, both coding and non-coding, based on a local simulation of the mutational processes affecting it. OncodriveFML possesses two critical advantages over the current generation of methods aimed at identifying cancer drivers. First, it can directly compute the FM bias—and thus identify drivers—of any genomic element, provided only that a score to assess the FI of somatic mutations can be computed for that element. In the “Results” section, we illustrate this versatility by employing different FI scoring approaches to detect putative cancer drivers among: (1) coding genes; (2) intronic splicing regions; (3) promoter regions; (4) untranslated regions (UTRs) of messenger RNAs (mRNA); and (5) long non-coding RNAs (lncRNAs). This feature will prove crucial as more cohorts of cancer tumors are sequenced at the whole-genome range opening up the possibility to detect non-coding elements involved in tumorigenesis. Second, the FM bias of genomic elements can still be computed if only one or few of them have been sequenced across the cohort of patients, as is the case of targeted sequencing aimed at informing clinical decision-making. This raises the possibility of dramatically lowering the cost of sequencing cohorts of tumors to carry out analyses such as the identification of genes involved in specific cancer-related processes, such as drug resistance, metastasis, and tumor relapse. We provide the source code of a web server to detect putative driver genomic elements, both coding and non-coding on mutations data from cohorts of tumors using OncodriveFML (http://www.intogen.org/oncodrivefml).
OncodriveFML computes a local FM bias
The rationale behind OncodriveFML is that the observation of somatic mutations on a genomic element (coding gene, promoter, UTR, lncRNA, etc) across tumors, whose average impact score is significantly greater than expected for said element constitutes a signal that these mutations have undergone positive selection during tumorigenesis. This, in turn is considered as a direct indication that this element drives tumorigenesis. We call this deviation of the observed average impact score of somatic mutation in a genomic feature from its expected value, the functional mutation bias, or FM bias. To measure the FM bias of a particular element, OncodriveFML is required to: (1) be able to compute a relevant score of the predicted impact of the mutations in the genomic element; and (2) simulate the mutational processes to compute the expected average impact score.
OncodriveFML consists of three steps illustrated in Fig. 1b–d. In the first step, the average FI score of the set of somatic mutations observed in the element of interest across a tumor cohort is computed (Fig. 1b). In the second step, sets of mutations of the same size as the number of mutations observed in the element are randomly sampled from the universe of all the variants that it can possibly sustain (Fig. 1c). To accurately model mutational processes in the tumor type of interest, the sampling is done following the probability of mutation of different tri-nucleotides, which can either be computed from the mutations observed in each sample, in cohort under analysis as a whole, or pre-computed from previously analyzed tumor cohorts of the same or similar type. This random sampling is iterated a number of times (e.g. 10,000 times) to generate local expected average impact scores. Finally, OncodriveFML compares the average impact score observed for each element to its local expected average impact score resulting from the sampling and computes a local FM bias, in the form of an empirical p value which measures the deviation of the observed average score from the expected background (Fig. 1d). Elements with significant local FM bias after the correction for false discovery rate are deemed likely drivers.
OncodriveFML detects driver coding genes
Second, as a proxy of the true positives rate of the method, we computed the fold enrichment in the proportion of known cancer genes (genes in the Cancer Gene Census (CGC) ) among its top ranking genes. We found that OncodriveFML performs better in this metric than the original version of OncodriveFM , MutSigCV , and e-Driver  (Fig. 2c and Additional file 2, section A) across the 19 cohorts of tumors analyzed. We also compared the results of OncodriveFML with a newer version of MutSigCV run by its authors , finding that there is an important overlap between the genes identified by both methods and that each method identifies additional true cancer genes missed by the other, stressing the complementarity of the two approaches (Additional file 2, section A). We next applied the OncodriveFML FM bias test to randomized datasets of mutations, built by reshuffling the mutations observed within each genome, following the rates of tri-nucleotides and the constraints of number of mutations per sample and per region. The number of genes detected as putative drivers within these random datasets of mutations would act as a proxy of the rate of false positive elements detected by the FM bias test. We carried out this analysis on the 19 whole-exome cohorts of tumors that constitute the WE-4482 dataset. OncodriveFML finds no significant gene in this dataset (gray dots in Fig. 2a), as expected for an accurate method with a low number of false positives. The whole list of driver candidates appears in Additional file 3. Taken together, the results presented in this section demonstrate that OncodriveFML identifies putative protein-coding driver genes with a sensitivity that outperforms five widely employed methods developed for this task, while maintaining a very low false positive rate.
OncodriveFML detects driver non-coding elements
OncodriveFML uncovers putative driver promoters and 5′ UTRs
In the pan-cancer cohort, comprising 505 tumors the promoter regions with the most significant FM bias comprise a shortlist of interesting candidate drivers, such as those of TERT (details in Fig. 3b), SYF2, ARGHEF18, and POLR2D. TERT encodes the reverse transcriptase subunit of telomerase required to maintain telomere length during tumor growth. Activating mutations in TERT promoter have been found as drivers in multiple types of cancer [12, 21, 22]. Other promising novel candidates include the promoters of SYF2 (details in Fig. 3c), an mRNA splicing factor thought to interact with a cell cycle regulator , ARHGEF18, a Rho-specific guanine nucleotide exchanging factor involved in RhoA activation and cell motility , and POLR2D (Fig. 3d), a subunit of the RNA polymerase, which contains mutations very close to the transcription start site (TSS) in melanoma samples [25, 26].
In a cohort of 18 lower grade gliomas, in addition to the TERT promoter, OncodriveFML identifies the promoter of SPN with a highly significant FM bias (Fig. 3e). The expression of both genes is significantly higher in samples bearing mutations in their promoters than in non-mutated samples (Fig. 3f), which provides foundation to the idea that these mutations are positively selected during tumorigenesis. SPN is normally produced solely by white blood cells where it regulates functions such as cell-cell adhesion, intracellular signaling, apoptosis, migration, and proliferation. Its ectopic expression in solid tumors has been reported and proposed as a target for immunotherapy . In summary, in addition to producing a very low rate of false positive results in the detection of putative driver promoter elements, OncodriveFML is able to identify already known and putative interesting promoters with driver mutations, even at very low mutational frequency. The whole list of putative driver promoters (and other non-coding elements) appears in Additional file 3.
Among top-ranking FM biased 5′ UTR regions, we found that of TBC1D12 (Fig. 3g). This gene encodes a GTPase-activating protein for Rab family proteins. 5′ UTR mutations are recurrently found near the start codon (Fig. 3h) and are detected in samples of different tumor types. We detected it also as FM biased in cohorts of the WG-608 dataset (Fig. 3i). The proximity of the mutations to the start codon suggests that they could have an effect on translational control. These mutations were recently reported as significantly redundant by , with 15 % of bladder tumor samples bearing mutations using whole-exome data.
OncodriveFML uncovers genes with driver mutations in splice intronic regions
We next analyzed with OncodriverFML the intronic regions of coding genes, specifically, the 50 bps from exon-intron boundary (intron-50 bps) using CADD as a functional scoring framework to identify genes with driver intron-splicing mutations. In the pan-cancer cohort, of the WG-505 dataset, OncodriveFML identifies a shortlist of well-known tumor suppressor genes—TP53, STK11, and NF1—as highly FM biased in their intron-splicing mutations (Fig. 4a-b). TP53 contains 16 mutations within the first 50 bps of its introns, seven of which appear in breast cancer samples, while the others are distributed across the cohorts of other tumor types (including GBM, CRC, LUSC, SKCM, LUAD) (Fig. 4b). Interestingly, eight of these mutations are within the first 2 bps of the intron-exon boundary. STK11 is a serine/threonine-protein kinase known to act as a tumor suppressor in the control of the activity of AMP-activated protein kinase (AMPK) family members, thereby playing a role in various processes such as cell metabolism, cell polarity, apoptosis, and DNA damage response, often bearing inactivating mutations in in lung adenocarcinomas [29, 30]. Most of the mutations (4 out of 6) observed in the pan-cancer cohort of the WG-505 dataset falling within the first 50 bps of its introns indeed correspond to lung adenocarcinoma samples and all are in close proximity to the intron-exon boundary (Fig. 4c).
OncodriveFML identifies putative driver 3′ UTRs
Next, we employed OncodriveFML to identify driver genes upon mutations in their 3′ UTR regions. In this case, we used the impact of mutations on RNA secondary structure computed by RNAsnp as FI score to compute the FM bias of mutations . In the pan-cancer cohort of the WG-505 dataset, OncodriveFML identified BORA and CHAF1B as putative driver genes from the mutations in their 3′ UTR regions (Fig. 4d–h). Mutations contributing to the computed FM bias for CHAF1B in the WG-505 dataset appear in BRCA, CRC, LUAD, and UCEC. On the other hand, in the pan-cancer cohort of the WG-608 dataset, where it also appears as significantly FM biased, mutations appear in BRCA and STAD samples (Fig. 4e). CHAF1B is a chromatin assembly factor implicated in DNA replication and DNA repair . BORA is an Aurora kinase activator, involved in the maturation of the centrosome, the assembly of the spindle and asymmetric protein localization during mitosis .
OncodriveFML identifies putative lncRNAs
We next employed OncodriveFML to explore the potential of a group of lncRNAs collected from the literature the biological functions of which have been established [34–36] (Additional file 4). The mutated lncRNAs among these (across cohorts in the WG-505 and WG-608 datasets) were thus analyzed by OncodriveFML and those significantly FM biased in at least one cohort appear in Additional file 4. As in the case of 3′ UTRs, we computed the FM bias using an FI metric that estimates the impact of mutation on the RNA secondary structure . We found that MALAT1, a lncRNA gene previously shown to be involved in tumorigenesis of lung adenocarcinomas , exhibits a slightly significant FM bias in cohorts of both the WG-505 (p value 0.0138 in KIRC) and the WG-608 (p value 0.0104 in pan-cancer) datasets. In addition, we detected a higher than expected accumulation of high functional impacting somatic mutations in MIAT, a non-protein-coding transcript associated with myocardial infarction in the WG-505 dataset (p value 0.0281 in CRC and p value 0.0163 in pan-cancer).
OncodriveFML detects positive selection from the sequence of a gene panel
We have made OncodriveFML available to cancer genomics researchers both to download and install the code and to run through a web application (http://www.intogen.org/oncodrivefml).
OncodriveFML introduces the construction of a local mutational background to compute the FM bias of genomic elements, a fundamental innovation which differentiates it from other methods designed to pick up signals of positive selection in genes across tumor samples. The local background model ensures that factors influencing the mutation rate in the large-scale—such as chromatin compaction or replication timing—do not result in over or underestimation of the FM bias of any genomic element. Other factors that affect the background mutation rate locally may still disturb the calculation of the FM bias of genomic elements and, as they are discovered, they should be incorporated into this local modeling, as is the case of transcription factor binding sites . The combination of this local-background-building approach and the compliance with the mutational signature in the construction of the background model for the FM bias result in very fine-tuned statistical test that produces a very low rate of false positives, effectively outperforming the current generation of methods to detect driver genomic elements, both coding and non-coding, as we have demonstrated in this article. Furthermore, in principle OncodriveFML could also be used to detect negative selection in the pattern of somatic or germline variants observed across cohorts of samples taken from either tumors or normal tissues.
Although the accuracy of OncodriveFML relies on the predicted FI of mutations, these predictions need not be accurate enough to correctly identify individual driver variants, because the method computes the average FI of mutations and compares it to the distribution of all possible mutations in the region. Since FI scores are more developed for coding mutations (as is the case with CADD, which includes more information to score coding mutations), OncodriveFML may currently lose non-coding driver regions where the FI of mutations is poorly assessed. Nevertheless, the development of new methods aimed at scoring non-coding mutations as more whole genomes of tumors are sequenced will improve the quality of OncodriveFML in non-coding regions. Furthermore, in all the results shown in this paper in non-coding genomic elements, the FM bias has been calculated exclusively based on nucleotide substitutions. Finding a way of accurately scoring the FI of indels in non-coding regions will probably contribute to uncover new putative driver non-coding elements.
As the application of next generation sequencing technologies moves into the clinic, sequencing panels of genes—or any genomic regions—rather than the whole exomes or whole genomes of cohorts of tumors will become the most frequent choice . Sequencing gene panels can also have important applications in research to detect subsets of known cancer genes that act as drivers or play other roles, such as drug resistance in specific cohorts of cancer patients. Here we have demonstrated that due to the computation of the local FM bias of genes, OncodriveFML is capable of detecting genes undergoing positive selection even if the catalog of all exomic mutations is not available for analysis. This capability will prove critical to analyze the results of sequencing panels.
Here we describe OncodriveFML, a novel method able to detect putative cancer driver genomic regions through the computation of a local FM bias. As we have shown, OncodriveFML is able to operate on both coding and non-coding genomic regions, or any combination thereof to reveal their involvement in tumorigenesis. Furthermore, due to its unique local background model of the FI of mutations it is able to detect signals of positive selection in tumorigenesis when only the sequence of a small portion of the genome is available, opening the opportunity to exploit data obtained from the interrogation of gene panels.
Tumor mutations datasets
We analyzed a dataset of somatic mutations detected by whole-exome sequencing (dataset WE-4482), two datasets of somatic mutations detected by whole-genome sequencing (datasets WG-608 and WG-505), and a dataset of somatic mutations detected in a panel of genes sequenced at high coverage (dataset GP-234). The first dataset (WE-4482) contains the somatic mutations of 19 cancer types, the results of four of which (lung squamous cell carcinoma, lung adenocarcinoma, skin cutaneous melanoma, and acute myeloid leukemia) are shown in Fig. 2. The sources of the dataset are listed in Additional file 1. The second dataset (dataset WG-608) contains the somatic mutations of seven cancer types (breast invasive carcinoma, chronic lymphocytic leukemia, liver cancer, lung adenocarcinoma, lymphoma B-cell, medulloblastoma, and pilocytic astrocytoma) extracted from the work by Alexandrov et al.  plus a supplementary stomach adenocarcinoma dataset . The third (dataset WG-505) contains the somatic mutations of 14 cancer types determined by TCGA . The fourth dataset (dataset GP-234) contains the somatic mutations detected in a panel of genes sequenced with high coverage across 234 biopsies of sun-exposed epidermis . The datasets were filtered to discard all possible false positives of the somatic mutations calling and we restricted the analyses to single nucleotide substitutions (SNV) excluding from the study both insertions and deletions. The number of samples and the number of mutations for each dataset are listed in Additional file 1.
Definition of the coordinates of genomic elements
The genomic coordinates of both coding genes and lncRNAs were obtained from the ENCODE website (http://www.gencodegenes.org/), using Gencode release 19. Specifically, the coordinates of genes were retrieved from ftp://ftp.sanger.ac.uk/pub/gencode/Gencode_human/release_19/gencode.v19.annotation.gtf.gz. We only consider CDS of genes where both the “gene_type” and the “transcript_type” metadata were annotated as “protein-coding.” We defined intronic splice sites as 50 bp regions at the edges of protein coding introns. We removed from the datasets of UTRs all overlapping coding regions and short intronic splice sites of 10 bp. In addition, we removed from 5′ UTRs any overlap with 3′ UTRs. Promoter regions were defined as sequences 2500 bp upstream the TSS of protein-coding genes. We also removed from the dataset of promoters any region previously annotated as protein-coding (CDS), as untranslated region (3′ UTR and 5′ UTR), or as short intronic splice site. Overlapping elements of the same type (CDS of the same gene, UTRs of the same gene, intronic splice sites of the same gene, or promoters of the same gene) were merged together. Finally, we manually discarded genomic elements that show any evidence of erroneous annotation.
The genomic coordinates of lncRNAs were obtained from ftp://ftp.sanger.ac.uk/pub/gencode/Gencode_human/release_19/gencode.v19.long_noncoding_RNAs.gtf.gz. We only considered the exons of lncRNAs where both the “gene_type” and the “transcript_type” metadata were annotated as “lincRNA.” We removed from the lncRNAs any region previously annotated as protein-coding (CDS), as untranslated region (3′ UTR and 5′ UTR), or as short intronic splice site. and we merged together overlapping exons of the same lncRNA.
Functional impact scoring metrics used in the analysis
The FI scores of all possible nucleotide changes in CDS and promoters of genes were retrieved from the CADD framework  version 1.0 (http://krishna.gs.washington.edu/download/CADD/v1.0/whole_genome_SNVs.tsv.gz). This framework provides a score of deleteriousness for every possible substitution of each nucleotide of the human genome and can consequently be applied to every coding or non-coding element of the genome. In the case of 3′ UTRs and lncRNAs, the FI for every possible substitution in each position was calculated using RNAsnp  to predict the impact of mutation on RNA secondary structure. The RNAsnp was executed with the “Mode 1” option (with other parameters set to default) to compute the local structural effect of mutations. For our analysis, we retrieved the resultant Euclidean distance score, which represents the difference between the base pair probabilities of wild-type and mutant ensemble structures as the basis to compute the FM bias.
OncodriveFML methodological details
OncodriveFML has the ability to use different scoring frameworks, such as CADD  or RNAsnp . Since the method is independent of the scoring system used, new scores can easily be incorporated to it as soon as they become available.
It first retrieves the FI score of all the mutations that can occur in an element (for instance, a gene or a UTR). The FI scores will vary depending on the scoring framework used (CADD, RNAsnp, etc.).
It then calculates the mean of the FI scores of all the observed mutations in the element across tumors.
- 3.It randomly takes from the pool of scores of all possible nucleotide changes in the element under analysis N samples of the same size as the number of observed mutations. The higher the N, the more resolution the derived empirical p values will have. For every random-generated mutation, its FI score is retrieved from the framework in use. The random sampling procedure can vary depending on the probability of each mutation to be sampled:
It can be assumed that all the random generated mutations have equal probability to occur.
It can be assumed that the probability of each mutation to occur is based on the mutational signatures (i.e. tri-nucleotide composition) observed in the dataset. For the analysis presented in this study we computed matrices of tri-nucleotide probabilities of the 96 possible changes (e.g. probability of ATC to mutate to ACC, probability of ATC to mutate to AGC, etc.). The matrices are computed by counting all the observed mutations in all the tumors. The random sampling process will thus take into account the different probabilities that each mutation has to occur. For instance, if a dataset show a higher frequency of the mutation ATT to ACT, the same mutation will be more likely to be sampled.
It computes the mean of each of the N random-generated group of mutations. N random sampling will generate a vector of N mean of FI scores.
It computes an empirical p value by comparing the mean of the observed FI scores with the distribution of means of the randomized FI scores. In brief, it counts how many times the mean of the observed FI scores is bigger than the means of the randomized FI scores, and then normalizes this value by the number of randomizations performed (N). For instance, if 10,000 randomizations have been computed (N is 10,000) and only two of these values are bigger than the mean of the observed FI scores, then the empirical p value would be 2/10,000, or 2*10–4. If the resulting p value is equal to 0, the number of randomizations N can be increased in order to gain a better p value resolution. The obtained p value indicates how likely the mean of the observed FI scores is expected by chance.
The resulting p values are then adjusted with a multiple testing correction using the Benjamini–Hochberg procedure. In the present study, we adjusted the p values of regions mutated in at least two samples in individual tumor types and five samples in the pan-cancer dataset.
Comparison of OncodriveFML to other methods in the identification of putative driver coding genes
The somatic mutations used in the comparison were detected by whole-exome sequencing across the tumors of 19 cohorts (4482 samples in total). The sources of the data along with the number of samples and the number of mutations of each cancer type are listed in Additional file 1. The list of known cancer genes (CGC)  were retrieved from the Catalog Of Somatic Mutations In Cancer (COSMIC): sftp://sftpcancer.sanger.ac.uk/files/grch38/cosmic/v72/cancer_gene_census.csv. MutSigCV (version 1.4) was run using default parameters and using the full coverage file and the genes covariates provided by the authors. OncodriveFM was run using default parameters but setting the gene threshold (i.e. minimum number of mutations per gene to compute the FM bias) to 1. e-Driver was run with the mode option set to 1 (DOM). To compare OncodriveFML with the most recent version of MutSigCV, not publicly available at the time of writing, we obtained the list of significant genes identified by MutSigCV as run directly by the authors from the web http://tumorportal.org/. Since p values are not provided, in this case it was not possible to compute the proportion of known cancer genes among the top ranking genes as in Fig. 2c, and instead we compared the set of overlapping genes between both methods (Additional file 2, section A). Further details of these comparisons appear in the text in Additional file 2.
Generation of datasets of random mutations
For each dataset of somatic mutations analyzed, we created a corresponding random dataset containing the same number of samples and the same number of somatic mutations (per sample) as the original dataset. The simulated mutations were randomly repositioned within windows of 50 Kb maintaining the original mutational signature, i.e. the same tri-nucleotide composition. The mutations whose reported reference allele was different from the corresponding position in the reference genome (hg19) were not included in the simulation.
Figures 2, 3, 4, 5 show the linear distribution of mutations along the sequence of a genomic element (gene, UTR, promoter, etc.). The positions of the mutations correspond to their relative location inside the element. If an element is fragmented in different segments, these are concatenated and the fragments are represented with vertical dashed lines. The y-axis, and thus the height of the dots, indicates how many mutations have been observed in a given position (i.e. number of samples that share the same mutation) and the color of the dots represents the functional impact (FI) score of each mutation in the element. The color scale is normalized by the range of scores presents in the element after considering all the possible mutations. The “>” and “<” signs inside the element denote its strand. The highest possible FI score of each position of the element is represented at the bottom of the needle plot. The p value of the element is reported at the top-right of the plot.
Precomputed expression data were retrieved from Fredriksson et al. . A detailed explanation of how the expression level were determined is provided in the original paper. In short, the authors obtained the RNA-sequencing (RNA-seq) and copy-number data (Affymetrix SNP6) from the cgHub repository (https://cghub.ucsc.edu). Gene expression level were subsequently determined by processing of raw sequencing data in BAM format considering the coding and lncRNA subsets of the GENCODE (v17) annotation and using HTSeq-count  as described in Akrami et al. . Copy-number amplitudes were determined from segmented data (Affymetric SNP6 platform) available from TCGA by considering the minimum amplitude of all overlapping copy-number segments for each gene.
The significance of the differential expression between mutated and non-mutated samples was assessed using a Wilcoxon rank-sum test. For a given gene and cancer type, the test was performed only if at least 25 % of tumors had a detectable expression (i.e. non-zero value). In addition, the copy-number alteration data were taken into account and copy number-altered samples were excluded from the analysis (i.e. absolute amplitude expressed in log2 scale >0.2). After applying the filtering, we required at least ten remaining samples per gene and cancer type in order to compare the expression of the two groups.
CADD, combined annotation dependent depletion; CGC, Cancer Gene Census; COSMIC, Catalog Of Somatic Mutations In Cancer; cSCC, cutaneous squamous cell carcinoma; FI, functional impact; FM bias, functional mutations bias; GP-234, dataset of a gene panel sequence of 234 tumor samples; TCGA, The Cancer Genome Atlas; WE-4482, dataset of whole-exome sequence of 4482 tumor samples; WG-505, dataset of whole-genome sequence of 505 tumor samples; WG-608, dataset of whole-genome sequence of 608 tumor samples
The results published here are in whole or part based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/.
We acknowledge funding from the Spanish Ministry of Economy and Competitiveness (SAF2015-66084-R, MINECO/FEDER, UE), the Marató de TV3 Foundation, and the Spanish National Institute of Bioinformatics (INB). R.S. is supported by an EMBO Long-Term Fellowship (ALTF 568-2014) co-funded by the European Commission (EMBOCOFUND2012, GA-2012-600394) support from Marie Curie Actions. A.G.-P. is supported by a Ramón y Cajal contract (RYC-2013-14554).
Availability of data and material
The code of OncodriveFML is freely available via a Bitbucket repository (https://bitbucket.org/bbglab/oncodrivefml), under a AGPL OSI-compliant license. Please note that while the evolution of the method will determine changes of the code in the aforementioned Bitbucket repository, the code of the OncodriveFML version employed to generate the results presented in this article (v1.0) is available at the zenodo repository (http://dx.doi.org/10.5281/zenodo.51834).
NL-B and AG-P designed the method. LM and JD-P implemented and tested it. RS computed the impact of mutations on RNA secondary structure. NL-B and AG-P wrote the manuscript. LM prepared the figures and participated in the writing of the manuscript. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
No ethics approval was required for the study, which is all based on publicly available data.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Weinstein JN, Collisson EA, Mills GB, Shaw KRM, Ozenberger BA, Ellrott K, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013;45:1113–20.View ArticlePubMedPubMed CentralGoogle Scholar
- ICGC. International network of cancer genome projects. Nature. 2010;464:993–8.View ArticleGoogle Scholar
- Gonzalez-Perez A, Mustonen V, Reva B, Ritchie GRS, Creixell P, Karchin R, et al. Computational approaches to identify functional genetic variants in cancer genomes. Nat Methods. 2013;10:723–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499:214–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Gonzalez-Perez A, Lopez-Bigas N. Functional impact bias reveals cancer drivers. Nucleic Acids Res. 2012;40:e169.View ArticlePubMedPubMed CentralGoogle Scholar
- Tamborero D, Gonzalez-Perez A, Lopez-Bigas N. OncodriveCLUST: Exploiting the positional clustering of somatic mutations to identify cancer genes. Bioinformatics. 2013;29:2238–44.View ArticlePubMedGoogle Scholar
- Reimand J, Bader GD. Systematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer drivers. Mol Syst Biol. 2013;9:637.View ArticlePubMedPubMed CentralGoogle Scholar
- Dees ND, Zhang Q, Kandoth C, Wendl MC, Schierding W, Koboldt DC, et al. MuSiC: Identifying mutational significance in cancer genomes. Genome Res. 2012;22:1589–98.View ArticlePubMedPubMed CentralGoogle Scholar
- Yates LR, Campbell PJ. Evolution of the cancer genome. Nat Rev Genet. 2012;13:795–806.View ArticlePubMedPubMed CentralGoogle Scholar
- Polak P, Karlic R, Koren A, Thurman R, Sandstrom R, Michael S, et al. Cell-of-origin chromatin organization shapes the mutational landscape of cancer. Nature. 2015;518:360–4.View ArticlePubMedPubMed CentralGoogle Scholar
- Weinhold N, Jacobsen A, Schultz N, Sander C, Lee W. Genome-wide analysis of noncoding regulatory mutations in cancer. Nat Genet. 2014;46:1160–5.View ArticlePubMedPubMed CentralGoogle Scholar
- Fredriksson NJ, Ny L, Nilsson JA, Larsson E. Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types. Nat Genet. 2014;46:1–7.View ArticleGoogle Scholar
- Smith KS, Yadav VK, Pedersen BS, Shaknovich R, Geraci MW, Pollard KS, et al. Signatures of accelerated somatic evolution in gene promoters in multiple cancer types. Nucleic Acids Res. 2015;43:5307–17.View ArticlePubMedPubMed CentralGoogle Scholar
- Lochovsky L, Zhang J, Fu Y, Khurana E, Gerstein M. LARVA: An integrative framework for large-scale analysis of recurrent variants in noncoding annotations. Nucleic Acids Res. 2015;43:8123–34.View ArticlePubMedPubMed CentralGoogle Scholar
- Cheng DT, Mitchell T, Zehir A, Shah RH, Benayed R, Syed A, et al. MSK-IMPACT: a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn. 2015;17:251–64.View ArticlePubMedGoogle Scholar
- Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J, et al. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46:310–5.View ArticlePubMedPubMed CentralGoogle Scholar
- Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, et al. A census of human cancer genes. Nat Rev Cancer. 2004;4:177–83.View ArticlePubMedPubMed CentralGoogle Scholar
- Porta-Pardo E, Godzik A. E-Driver: A novel method to identify protein regions driving cancer. Bioinformatics. 2014;30:3109–14.View ArticlePubMedPubMed CentralGoogle Scholar
- Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505:495–501.View ArticlePubMedPubMed CentralGoogle Scholar
- Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio Jr SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–21.View ArticlePubMedPubMed CentralGoogle Scholar
- Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science. 2013;339:957–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, et al. TERT promoter mutations in familial and sporadic melanoma. Science. 2013;339:959–61.View ArticlePubMedGoogle Scholar
- Liu Y, Ni T, Xue Q, Lv L, Chen B, Cui X, et al. Involvement of p29/SYF2/fSAP29/NTC31 in the progression of NSCLC via modulating cell proliferation. Pathol Res Pract. 2015;211:36–42.View ArticlePubMedGoogle Scholar
- Song C, Gao Y, Tian Y, Han X, Chen Y, Tian DL. Expression of p114RhoGEF predicts lymph node metastasis and poor survival of squamous-cell lung carcinoma patients. Tumor Biol. 2013;34:1925–33.View ArticleGoogle Scholar
- Jacquemont C, Taniguchi T. Proteasome function is required for DNA damage response and fanconi anemia pathway activation. Cancer Res. 2007;67:7395–405.View ArticlePubMedGoogle Scholar
- Gemoll T, Habermann JK, Becker S, Szymczak S, Upender MB, Bruch HP, et al. Chromosomal aneuploidy affects the global proteome equilibrium of colorectal cancer cells. Anal Cell Pathol. 2013;36:149–61.View ArticleGoogle Scholar
- Tuccillo FM, Palmieri C, Fiume G, de Laurentiis A, Schiavone M, Falcone C, et al. Cancer-associated CD43 glycoforms as target of immunotherapy. Mol Cancer Ther. 2014;13:752–62.View ArticlePubMedGoogle Scholar
- Araya CL, Cenik C, Reuter JA, Kiss G, Pande VS, Snyder MP, et al. Identification of significantly mutated regions across cancer types highlights a rich landscape of functional molecular alterations. Nat Genet. 2016;48:117–25.View ArticlePubMedGoogle Scholar
- Collisson EA, Campbell JD, Brooks AN, Berger AH, Lee W, Chmielecki J, et al. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543–50.View ArticleGoogle Scholar
- Sanchez-Cespedes M, Parrella P, Esteller M, Nomoto S, Trink B, Engles JM, et al. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res. 2002;62:3659–62.PubMedGoogle Scholar
- Sabarinathan R, Tafer H, Seemann SE, Hofacker IL, Stadler PF, Gorodkin J. RNAsnp: efficient detection of local RNA secondary structure changes induced by SNPs. Hum Mutat. 2013;34:546–56.View ArticlePubMedPubMed CentralGoogle Scholar
- Kaufman PD, Kobayashi R, Kessler N, Stillman B. The p150 and p60 subunits of chromatin assembly factor I: a molecular link between newly synthesized histones and DNA replication. Cell. 1995;81:1105–14.View ArticlePubMedGoogle Scholar
- Hutterer A, Berdnik D, Wirtz-Peitz F, Zigman M, Schleiffer A, Knoblich JA. Mitotic activation of the kinase aurora-a requires its binding partner bora. Dev Cell. 2006;11:147–57.View ArticlePubMedGoogle Scholar
- Ruiz-Orera J, Messeguer X, Subirana JA, Alba MM. Long non-coding RNAs as a source of new peptides. Elife. 2014;3:e03523.View ArticlePubMedPubMed CentralGoogle Scholar
- Prensner JR, Iyer MK, Balbin OA, Dhanasekaran SM, Cao Q, Brenner JC, et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotech. 2011;29:742–9.View ArticleGoogle Scholar
- Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D, et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci U S A. 2009;106:11667–72.View ArticlePubMedPubMed CentralGoogle Scholar
- Gutschner T, Hämmerle M, Diederichs S. MALAT1 - A paradigm for long noncoding RNA function in cancer. J Mol Med. 2013;791–801.Google Scholar
- Martincorena I, Roshan A, Gerstung M, Ellis P, Van Loo P, McLaren S, et al. High burden and pervasive positive selection of somatic mutations in normal human skin. Science (80-). 2015;348:880–6.View ArticleGoogle Scholar
- Sabarinathan R, Mularoni L, Deu-Pons J, Gonzalez-Perez A, Lopez-Bigas N. Nucleotide excision repair is impaired by binding of transcription factors to DNA. Nature. 2016;532:264–7.View ArticlePubMedGoogle Scholar
- Lechner M, Frampton GM, Fenton T, Feber A, Palmer G, Jay A, et al. Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumors. Genome Med. 2013;5:49.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang K, Yuen ST, Xu J, Lee SP, Yan HHN, Shi ST, et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet. 2014;46:573–82.View ArticlePubMedGoogle Scholar
- Anders S, Pyl PT, Huber W. HTSeq – A Python framework to work with high-throughput sequencing data. Bioinformatics. 2015;31:166–9.Google Scholar
- Akrami R, Jacobsen A, Hoell J, Schultz N, Sander C, Larsson E. Comprehensive analysis of long non-coding RNAS in ovarian cancer reveals global patterns and targeted DNA amplification. PLoS One. 2013;8:e80306.Google Scholar